Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials
Annals of Pharmacotherapy · 2023
DOI: 10.1177/10600280231162243 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Annals of Pharmacotherapy, 2023. Verfasst von Akhil Deepak Vatvani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Fluvoxamine may be beneficial for the management of coronavirus disease 2019 (Covid-19) because of its effect on the sigma-1 receptor. Available evidence from randomized clinical trials (RCTs) has shown conflicting results.
Objective
This study sought to analyze the efficacy and safety of fluvoxamine as an outpatient treatment for Covid-19.
Methods
Using specific keywords, we comprehensively go through the potential articles on PubMed, Scopus, Europe PMC, and ClinicalTrials.gov sources until February 1, 2023. We collected all published clinical trials on fluvoxamine and Covid-19. We were using Review Manager 5.4 to conduct statistical analysis.
Results
We include a total of 6 trials. Our pooled analysis revealed that fluvoxamine did not offer any significant benefit when compared with placebo in reducing the risk of clinical deterioration (risk ratio [RR] = 0.83; 95% CI: 0.65-1.06, P = 0.14, I 2 = 29%), and hospitalization (RR = 0.80; 95% CI: 0.62-1.04, P = 0.09, I 2 = 0%) of Covid-19 outpatients. The serious adverse events did not differ significantly between the 2 groups. Conclusions and Relevance: This study indicates that although safe, fluvoxamine was not effective for outpatient treatment of Covid-19. Until more evidence can be obtained from larger RCTs, our study did not encourage the use of fluvoxamine as routine management for patients with Covid-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.
- Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.
ORCID-Profile: Timotius Ivan Hariyanto
Zitieren
APA
Vatvani, A. D., Kurniawan, A., & Hariyanto, T. I. (2023). Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231162243
Vancouver
Vatvani AD, Kurniawan A, Hariyanto TI. Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials. Annals of Pharmacotherapy. 2023. doi:10.1177/10600280231162243
BibTeX
@article{Vatvani2023,
author = {Vatvani, Akhil Deepak and Kurniawan, Andree and Hariyanto, Timotius Ivan},
title = {Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials},
journal = {Annals of Pharmacotherapy},
year = {2023},
doi = {10.1177/10600280231162243}
}
EUVIMED